Results of an interim analysis of the Phase III trials conducted by Oxford University with AZD1222 peer-reviewed and published in The Lancet on Wednesday, demonstrated that the vaccine is safe and effective at preventing symptomatic Covid-19 and that it protects against severe disease and hospitalization.
AstraZeneca announced Monday that positive high-level results from an interim analysis of clinical trials of its Covid-19 vaccine candidate in the UK and Brazil showed it was highly effective
The trials will enroll approximately 30,000 adult volunteers at 80 sites in the US to evaluate if the candidate vaccine, known as AZD1222, can prevent symptomatic Covid-19
IANS Amid the race to develop an effective vaccine against COVID-19 in record time, six candidates have now entered the late stage clinical trial, according to The New York Times vaccine tracker. The latest entrants in this crucial phase of vaccine development are Moderna and the one jointly developed by US-based Pfizer and German biotech […]
IANS The Serum Institute of India (SII) will be making one billion doses of Covishield vaccine — the vaccine being developed in collaboration with Oxford University — over the next one year for India and other low-and-middle-income countries. SII CEO Adar Poonawalla told IANS in an interview that “by the first quarter of the next […]
The COVID-19 vaccine being produced by the Oxford Vaccine Group indicate no early safety concerns and induces strong immune responses in both parts of the immune system, the British university’s division said Monday.
